FDA orders CytRx to stop arimoclomol drug trial

01/22/2008 | American City Business Journals

The FDA has asked CytRx Corp. to halt a clinical trial of its Lou Gehrig's disease drug candidate, arimoclomol, and provide additional data on previous animal studies involving the treatment, the company said Tuesday. The Los Angeles-based biopharmaceutical firm stated that "arimoclomol has been shown to be safe and well-tolerated after being administered to about 185 study volunteers."

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD